NasdaqCM:APOP

Stock Analysis Report

Executive Summary

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Cellect Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APOP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

35.3%

APOP

1.4%

US Life Sciences

-2.0%

US Market


1 Year Return

-57.8%

APOP

-8.1%

US Life Sciences

-15.1%

US Market

Return vs Industry: APOP underperformed the US Life Sciences industry which returned -8.1% over the past year.

Return vs Market: APOP underperformed the US Market which returned -15.1% over the past year.


Shareholder returns

APOPIndustryMarket
7 Day35.3%1.4%-2.0%
30 Day-24.5%-14.5%-19.7%
90 Day-16.4%-16.3%-23.2%
1 Year-57.8%-57.8%-8.0%-8.1%-13.4%-15.1%
3 Year-95.2%-95.2%59.2%58.1%10.9%3.7%
5 Yearn/a80.3%77.8%28.4%14.4%

Price Volatility Vs. Market

How volatile is Cellect Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cellect Biotechnology undervalued compared to its fair value and its price relative to the market?

0.91x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APOP is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: APOP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APOP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APOP is good value based on its PB Ratio (0.9x) compared to the US Life Sciences industry average (4.3x).


Next Steps

Future Growth

How is Cellect Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cellect Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cellect Biotechnology performed over the past 5 years?

-20.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APOP is currently unprofitable.

Growing Profit Margin: APOP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APOP is unprofitable, and losses have increased over the past 5 years at a rate of -20.4% per year.

Accelerating Growth: Unable to compare APOP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APOP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21.5%).


Return on Equity

High ROE: APOP has a negative Return on Equity (-78.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cellect Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: APOP's short term assets (₪22.5M) exceed its short term liabilities (₪3.5M).

Long Term Liabilities: APOP's short term assets (₪22.5M) exceed its long term liabilities (₪3.6M).


Debt to Equity History and Analysis

Debt Level: APOP is debt free.

Reducing Debt: APOP had no debt 5 years ago.


Balance Sheet

Inventory Level: APOP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if APOP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APOP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: APOP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -33% each year


Next Steps

Dividend

What is Cellect Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APOP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate APOP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APOP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APOP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APOP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Shai Yarkoni (61yo)

6.75s

Tenure

₪2,833,000

Compensation

Dr. Shai Yarkoni, M.D., Ph.D., co-founded Cellect Biotherapeutics subsidiary of Cellect Biotechnology Ltd. in 2011. He has been the Chief Executive Officer of Cellect Biotechnology Ltd. since July 04, 2013 ...


CEO Compensation Analysis

Compensation vs Market: Shai's total compensation ($USD779.50K) is about average for companies of similar size in the US market ($USD618.59K).

Compensation vs Earnings: Shai's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shai Yarkoni
Co-Founder6.75yrs₪2.83m4.39% 294.5k
Eyal Leibovitz
Chief Financial Officer3.25yrs₪1.64m0.023% 1.5k
Yael Kenan
Vice President of Clinical Affairs4.25yrs₪749.00kno data
Amos Ofer
Vice President of Operationsno datano datano data
Andrew Sabatier
Chief Business Officer1.92yrsno data0.019% 1.2k
Amotz Nechushtan
Vice President of Research & Development4.75yrs₪576.00kno data

4.3yrs

Average Tenure

57yo

Average Age

Experienced Management: APOP's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shai Yarkoni
Co-Founder6.75yrs₪2.83m4.39% 294.5k
Susan Alpert
Member of Advisory Boardno datano datano data
Jonathan Burgin
External Director1.5yrsno datano data
Robert Negrin
Member of Advisory Boardno datano datano data
John DiPersio
Member of Advisory Boardno datano datano data
Abraham Nahmias
Independent Director5.75yrsno data0.041% 2.8k
Dov Zipori
Member of Advisory Boardno datano datano data
Francesco Dazzi
Member of the Scientific Advisory Teamno datano datano data
Corey Cutler
Member of Advisory Board3.17yrsno datano data
David Braun
Independent Director2.33yrsno datano data

3.2yrs

Average Tenure

61yo

Average Age

Experienced Board: APOP's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49%.


Top Shareholders

Company Information

Cellect Biotechnology Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cellect Biotechnology Ltd.
  • Ticker: APOP
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.709m
  • Shares outstanding: 3.24m
  • Website: https://www.cellect.co

Number of Employees


Location

  • Cellect Biotechnology Ltd.
  • 23 Hata’as Street
  • Kfar Saba
  • 44425
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APOPNasdaqCM (Nasdaq Capital Market)YesSPONSORD ADS NEWUSUSDJul 2016
2EBADB (Deutsche Boerse AG)YesSPONSORD ADS NEWDEEURJul 2016

Biography

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in’s identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 11:09
End of Day Share Price2020/04/03 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.